You've just added:

Home / News

News + Media

February 23, 2023

Discovery of Potential New Way to Prevent Vision Loss

UVA Health School of Medicine scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss. Continue Reading

February 14, 2023

Broad ALS Targets Show Signs of Success in Treating Genetic and Sporadic Forms

Studies published from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments. Continue Reading

February 14, 2023

Thylacine Biotherapeutics Licenses Novel Antiviral Peptide Platform from Columbia University

Thylacine Biotherapeutics Inc. entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform. Continue Reading

February 10, 2023

Potential Therapeutic Target for Blood Cancers Discovered

Investigators discovered that a specific complex drives cell proliferation in different forms of blood cancers called mutated myeloproliferative neoplasms (MPNs), suggesting the complex could serve as an ideal therapeutic target for blood cancer. Continue Reading

February 08, 2023

Single Drug Injection Wards off COVID-19 Hospitalizations, in Stanford Medicine-Led Trial

In an international, multicenter, pivotal Phase 3 trial, a single under-the-skin injection of a biological drug given to patients within seven days of the onset of COVID-19 symptoms cut the likelihood they needed to be hospitalized in half. Continue Reading

January 27, 2023

Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm

Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc. Continue Reading

January 24, 2023

New Oral Compound Developed by Mass General Researchers May Help Prevent and Treat Osteoporosis

A team led by investigators at Massachusetts General Hospital (MGH), including Marc Wein, MD, PhD, Massachusetts General Hospital, 2018 Harrington Scholar-Innovator, might lead to a new, more convenient drug for preventing and treating osteoporosis. Continue Reading

November 22, 2022

ASU Researchers Developing Pioneering Drug to Treat Alzheimer's Disease in Down Syndrome Patients

Travis Dunckley, PhD, University of Arizona, 2016 ADDF-Harrington Scholar and team have developed a candidate drug they hope may successfully block the development or advancement of Alzheimer’s disease in Down syndrome patients. Continue Reading

October 19, 2022

PIC Closes $35M Series A to Advance Novel Breast Cancer Therapeutic

PIC Therapeutics has closed a $35 million Series A financing round centered around the advancement of its lead asset, a novel therapeutic for advanced metastatic breast cancer. Continue Reading

August 18, 2022

Harrington Scholar Developing a Universal Therapeutic that can Prevent and Treat All Strains of Influenza A

Harrington Scholar developing a universal treatment to prevent and treat influenza A. Continue Reading